Repurposing treprostinil for enhancing hematopoietic progenitor cell transplantation

Molecular Pharmacology

Volumn 89, Issue 6, 2016, Pages 630-644

  Kazemi, Zahra ^a   Bergmayr, Christian ^a   Prchal Murphy, Michaela ^b   Javaheri, Tahereh ^c   Themanns, Madeleine ^a   Pham, Ha T T ^c   Strohmaier, Wolfgang ^d   Sexl, Veronika ^b   Freissmuth, Michael ^a   Zebedin Brandl, Eva ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d SciPharm SàRL   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYCLIC AMP; FORSKOLIN; TREPROSTINIL; CHOLERA TOXIN; PROSTACYCLIN; PROSTACYCLIN RECEPTOR; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ARTICLE; BONE MARROW; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL ISOLATION; CELL MIGRATION ASSAY; CELL VIABILITY; DRUG EFFICACY; DRUG REPOSITIONING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; TREATMENT DURATION; UMBILICAL CORD BLOOD; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; HEMATOPOIETIC STEM CELL; METABOLISM; SURVIVAL ANALYSIS; WHOLE BODY RADIATION;

ANIMALS; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL CYCLE; CELL DIFFERENTIATION; CELL SURVIVAL; CHEMOKINE CXCL12; CHOLERA TOXIN; COLFORSIN; CYCLIC AMP; DRUG REPOSITIONING; EPOPROSTENOL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MICE, INBRED BALB C; RECEPTORS, CXCR4; RECEPTORS, EPOPROSTENOL; SURVIVAL ANALYSIS; WHOLE-BODY IRRADIATION;

EID: 84974530219     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.116.103267     Document Type: Article

References (40)

1. Adams GB, Alley IR, Chung UI, Chabner KT, Jeanson NT, Lo Celso C, Marsters ES, Chen M, Weinstein LS, and Lin CP et al. (2009) Haematopoietic stem cells depend on Galpha(s)-mediated signalling to engraft bone marrow. Nature 459:103-107.
2. Adams GB, Chabner KT, Alley IR, Olson DP, Szczepiorkowski ZM, Poznansky MC, Kos CH, Pollak MR, Brown EM, and Scadden DT (2006) Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 439:599-603.
3. Aksentijevich I and Flinn I (2002) Chemotherapy and bone marrow reserve: lessons learned from autologous stem cell transplantation. Cancer Biother Radiopharm 17:399-403.
4. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, and Harmar AJ; CGTP Collaborators (2013) The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170:1459-1581.
5. Aronoff DM, Peres CM, Serezani CH, Ballinger MN, Carstens JK, Coleman N, Moore BB, Peebles RS, Faccioli LH, and Peters-Golden M (2007) Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. J Immunol 178:1628-1634.
6. Benza RL, Tapson VF, Gomberg-Maitland M, Poms A, Barst RJ, and McLaughlin VV (2013) One-year experience with intravenous treprostinil for pulmonary arterial hypertension. J Heart Lung Transplant 32:889-896.
7. Bergmayr C, Thurner P, Keuerleber S, Kudlacek O, Nanoff C, Freissmuth M, and Gruber CW (2013) Recruitment of a cytoplasmic chaperone relay by the A2A adenosine receptor. J Biol Chem 288:28831-28844.
8. 2 treatment enhances engraftment of mouse bone marrow hematopoietic stem cells. Blood Cells Mol Dis 53:34-38.
9. Chi AK, Soubani AO, White AC, and Miller KB (2013) An update on pulmonary complications of hematopoietic stem cell transplantation. Chest 144:1913-1922.
10. Cutler C, Multani P, Robbins D, Kim HT, Le T, Hoggatt J, Pelus LM, Desponts C, Chen YB, and Rezner B et al. (2013) Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 122:3074-3081.
11. Freissmuth M and Gilman AG (1989) Mutations of GS alpha designed to alter the reactivity of the protein with bacterial toxins. Substitutions at ARG187 result in loss of GTPase activity. J Biol Chem 264:21907-21914.
12. Frisch BJ, Porter RL, Gigliotti BJ, Olm-Shipman AJ, Weber JM, O'Keefe RJ, Jordan CT, and Calvi LM (2009) In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. Blood 114:4054-4063.
13. Fukuda R, Kelly B, and Semenza GL (2003) Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 63:2330-2334.
14. Goessling W, Allen RS, Guan X, Jin P, Uchida N, Dovey M, Harris JM, Metzger ME, Bonifacino AC, and Stroncek D et al. (2011) Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 8:445-458.
15. Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL, Weidinger G, Puder M, Daley GQ, and Moon RT et al. (2009) Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell 136:1136-1147.
16. Hatse S, Princen K, Bridger G, De Clercq E, and Schols D (2002) Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 527:255-262.
17. Hoggatt J, Mohammad KS, Singh P, Hoggatt AF, Chitteti BR, Speth JM, Hu P, Poteat BA, Stilger KN, and Ferraro F et al. (2013a) Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature 495:365-369.
18. Hoggatt J, Singh P, Sampath J, and Pelus LM (2009) Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 113:5444-5455.
19. Hoggatt J, Singh P, Stilger KN, Plett PA, Sampson CH, Chua HL, Orschell CM, and Pelus LM (2013b) Recovery from hematopoietic injury by modulating prostaglandin E(2) signaling post-irradiation. Blood Cells Mol Dis 50:147-153.
20. Insel PA, Zhang L, Murray F, Yokouchi H, and Zambon AC (2012) Cyclic AMP is both a pro-apoptotic and anti-apoptotic second messenger. Acta Physiol (Oxf) 204:277-287.
21. Jiang J and Dingledine R (2013) Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther 344:360-367.
22. Johnson RA, Alvarez R, and Salomon Y (1994) Determination of adenylyl cyclase catalytic activity using single and double column procedures. Methods Enzymol 238:31-56.
23. Kudlacek O, Mitterauer T, Nanoff C, Hohenegger M, Tang WJ, Freissmuth M, and Kleuss C (2001) Inhibition of adenylyl and guanylyl cyclase isoforms by the antiviral drug foscarnet. J Biol Chem 276:3010-3016.
24. North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, Weber GJ, Bowman TV, Jang IH, and Grosser T et al. (2007) Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 447:1007-1011.
25. Pelus LM, Hoggatt J, and Singh P (2011) Pulse exposure of haematopoietic grafts to prostaglandin E2 in vitro facilitates engraftment and recovery. Cell Prolif 44 (Suppl 1):22-29.
26. Piccoli C, Agriesti F, Scrima R, Falzetti F, Di Ianni M, and Capitanio N (2013) To breathe or not to breathe: the haematopoietic stem/progenitor cells dilemma. Br J Pharmacol 169:1652-1671.
27. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, and Olson A et al. (2015) Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125:2885-2892.
28. Purton LE and Scadden DT (2007) Limiting factors in murine hematopoietic stem cell assays. Cell Stem Cell 1:263-270.
29. Reagan-Shaw S, Nihal M, and Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659-661.
30. Sadushi-Koliçi R, Skoro-Sajer N, Zimmer D, Bonderman D, Schemper M, Klepetko W, Glatz J, Jakowitsch J, and Lang IM (2012) Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension. J Heart Lung Transplant 31:735-743.
31. Scholz W, Platzer B, Schumich A, Höcher B, Fritsch G, Knapp W, and Strobl H (2004) Initial human myeloid/dendritic cell progenitors identified by absence of myeloperoxidase protein expression. Exp Hematol 32:270-276.
32. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, and Mangada J et al. (2005) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 174:6477-6489.
33. Siehr SL, Ivy DD, Miller-Reed K, Ogawa M, Rosenthal DN, and Feinstein JA (2013) Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics. J Heart Lung Transplant 32:546-552.
34. Speth JM, Hoggatt J, Singh P, and Pelus LM (2014) Pharmacologic increase in HIF1α enhances hematopoietic stem and progenitor homing and engraftment. Blood 123:203-207.
35. Sunahara RK, Dessauer CW, and Gilman AG (1996) Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36:461-480.
36. Tesmer JJ, Sunahara RK, Gilman AG, and Sprang SR (1997) Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS. Science 278:1907-1916.
37. Whittle BJ, Silverstein AM, Mottola DM, and Clapp LH (2012) Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol 84:68-75.
38. Wingard JR, Hsu J, and Hiemenz JW (2011) Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am 25:101-116.
39. Woodward DF, Jones RL, and Narumiya S (2011) International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 63:471-538.
40. Zon L (2014) Translational research: the path for bringing discovery to patients. Cell Stem Cell 14:146-148.